Revive Therapeutics — Fact Sheet (February 2022)

2 slides from Revive Therapeutics's fact sheet, February 2022

Slide 1: Corporate Fact Sheet H1-2022
Corporate Fact Sheet H1-2022 OVERVIEW  Focus on repurposing drugs for rare & infectious diseases  Awarded FDA Orphan Drug Status for CBD in the  Advancing clinical development of Bucillamine for treatment of Autoimmune Hepatitis infectious diseases, including COVID-19 (FDA Phase 3)  Prioritize d
Slide 2: Revive Therapeutics Ltd. | 82 Richmond Street East, Toronto, ON M5C 1P1 | 1-888-901-0036
Revive Therapeutics Ltd. | 82 Richmond Street East, Toronto, ON M5C 1P1 | 1-888-901-0036 | [email protected] | revivethera.com